Global Hypofibrinogenemia Market - 2024-2031

Global Hypofibrinogenemia Market - 2024-2031

Global Hypofibrinogenemia Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.

Hypofibrinogenemia is a rare congenital coagulation abnormality, often part of a broader coagulation abnormality. An immunologic test is needed when a functional test shows a low level, which may indicate normal or raised levels in dysfibrinogenemia. High levels may be associated with cardiovascular disease.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of bleeding disorders

The rise in bleeding disorders, particularly hypofibrinogenemia, is a significant market driver due to its genetic impact on blood clotting formation, necessitating increased demand for treatments and therapies.

For instance, bleeding disorders are a group of conditions that result when the blood cannot clot properly. Around one in 2,000 men, women, and children in the UK have a diagnosed bleeding disorder, which is almost always inherited.

The most common is von Willebrand disorder (VWD), which affects slightly more women than men, with 7,625 women and 4,310 men diagnosed in the UK (though many thousands remain undiagnosed). Perhaps the most well-known bleeding disorder is hemophilia A, which predominantly, but not exclusively, affects men.

Side effects associated with the treatment

Fibrinogen concentrates are purified proteins from human plasma used to replenish fibrinogen levels in patients. Common side effects that hinder the market include allergic reactions, mild fever, thrombosis risk, and headaches. Patients may experience rash, itching, hives, fever, blood clot formation, and pulmonary embolism. It is important to consult a healthcare professional before using this medication.

Segment Analysis

The global hypofibrinogenemia market is segmented based on treatment type, application, end-user, and region.

The fibrinogen concentrates from the treatment type segment accounted for approximately 47.3% of the hypofibrinogenemia market share

The fibrinogen concentrates from the treatment type segment accounted for approximately 47.3%. Fibrinogen concentrate is currently approved for the treatment of patients with congenital hypofibrinogenemia or afibrinogenemia and is now considered for treating hypofibrinogenemia during hemorrhage.

For instance, in June 2024, Plasmagen Biosciences Private Limited, a Bengaluru-based biopharmaceutical company, licensed Haemocomplettan P (Human Fibrinogen Concentrate) to treat and prevent hemorrhagic diatheses in acquired hypofibrinogenemia and congenital afibrinogenemia. The product, produced by global leader CSL Behring, will only be marketed in India by Plasmagen.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like FDA approvals, advancement in treatment options, new product launches, advanced healthcare infrastructure, and other factors that help the region to grow during the forecast period.

For instance, in June 2022, The National Institute of Excellence in Health and Social Services evaluation (INESSS) report on Fibryga acknowledged its therapeutic value as a complementary therapy for managing severe bleeding during surgical interventions in patients with fibrinogen deficiency. The report supports this opinion, supported by two main studies: FIBRES2 and FORMA-053, which show Fibryga's non-inferiority compared to cryoprecipitate during cardiac surgery.

Market Segmentation

By Treatment Type

● Fibrinogen Concentrates
Human Fibrinogen Concentrates
Animal-derived Fibrinogen Concentrates

● Cryoprecipitate

● Fresh Frozen Plasma (FFP)

By Application

● Congenital Hypofibrinogenemia

● Acquired Hypofibrinogenemia

● Others

By End-User

● Hospitals

● Specialty Clinics

● Research and Academic Institutes

By Region

● North America
U.S.
Canada
Mexico

● Europe
Germany
UK
France
Italy
Spain
Rest of Europe

● South America
Brazil
Argentina
Rest of South America

● Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific

● Middle East and Africa

Competitive Landscape

The major global players in the market include CSL Behring, Grifols, S.A., Kedrion Biopharma Inc., Octapharma AG, LFB S.A., Shanghai RAAS Blood Products Co., Ltd, Hualan Biological Engineering Inc, China Biologic Products Holdings, Inc, Baxter International Inc, Sanquin among others.

Why Purchase the Report?

● To visualize the global hypofibrinogenemia market segmentation based on treatment type, application, end user and region as well as understand key commercial assets and players.

● Identify commercial opportunities by analyzing trends and co-development.

● Excel data sheet with numerous data points of the hypofibrinogenemia market level with all segments.

● PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

● Product mapping available as excel consisting of key products of all the major players.

The global hypofibrinogenemia market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies